Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children

Inclusion Criteria: 1. Age 0 to \<19 years old 2. Hospitalized with symptoms compatible with COVID-19 illness 3. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen prior to randomization. 4. ABO compatible convalescent plasma available Exclusion Criteria: 1. Onset of symptoms began \>12 days before screening 2. History of adverse reactions to blood products or other contraindication to transfusion 3. Refusal of plasma for religious or other reasons 4. Acute heart failure with fluid overload 5. Any condition or diagnosis, that could in the opinion of the Site Principal Investigator interfere with the participant's ability to comply with study instructions, or put the participant at risk 6. Anticipated discharge within 24 hours Note: The intent of this exclusion criteria is to only include participants with acute COVID-19 infections. This protocol is not intended to include participants with post-infectious complications. In cases where the distinction is not clear, participant eligibility will be discussed with the study steering committee prior to enrollment.